#None #Clinical Trials #ProofPilot #Lokavant

ProofPilot's Game-Changing Acquisition of Lokavant

In a significant move for the clinical research landscape, ProofPilot, a recognized leader in the clinical experience platform sector, has announced its acquisition of Lokavant, a company renowned for its innovative clinical trial intelligence solutions. This strategic union aims to enhance clinical trial performance through the integration of cutting-edge predictive analytics, making it a transformative moment not only for both entities but also for the entire biopharma industry.

Founded as a spin-off from Roivant in 2020, Lokavant has established itself at the forefront of utilizing historical and real-time data to deliver predictive insights. Its sophisticated analytics tools are designed to optimize study feasibility and effectively mitigate operational risks in clinical trial execution. By leveraging Lokavant’s advanced technology, ProofPilot is set to provide sponsors and Contract Research Organizations (CROs) with an unprecedented ability to anticipate challenges, thereby accelerating the journey from clinical trials to the delivery of new therapies.

Chris Venezia, the CEO of ProofPilot, remarked on this acquisition, emphasizing the commitment of both companies to empower research teams. He highlighted that combining Lokavant's predictive analytics capabilities with ProofPilot's robust trial execution functionalities creates a comprehensive platform that enables users to measure and predict success in real-time. This integration means that stakeholders can analyze behaviors and study data simultaneously, leading to more informed decision-making.

The combined platform offers a data-driven approach to trial management, ensuring clinical researchers have an intuitive experience throughout the process. The AI-driven study forecasting feature not only supports proactive scenario planning but also allows users to manage recruitment campaigns effectively. Importantly, real-time performance dashboards provide continuous monitoring during study execution, thereby enhancing oversight capabilities. This integrated system aims to boost data quality and ensure regulatory compliance by incorporating site training based on emerging signals regarding protocol adherence and data accuracy.

As explained by Alex Gasner, EVP of Roivant Health, this merger aligns with Roivant's core mission: enhancing patients' lives by expediting the development and commercialization of pivotal medicines. By combining the strengths of Lokavant's data-driven insights with ProofPilot's trial experience platform, the biopharma industry gains the ability to deliver innovative solutions to patients with increased precision and speed.

Rohit Nambisan, CEO and Co-Founder of Lokavant, also shared his excitement regarding the merger, pointing out that it symbolizes a new standard in how clinical trials are designed and executed. By bringing together proof pilot’s innovative operational framework and Lokavant's predictive analytics, sponsors and CROs now possess invaluable clarity and foresight into study performance. This collaboration empowers them to make smarter plans, adapt swiftly to changes, and ultimately bring novel therapies to market more efficiently.

With this acquisition, ProofPilot reinforces its status as a frontrunner in clinical trial innovation. The comprehensive platform not only streamlines digital trial planning and execution but also augments it with predictive intelligence designed to maximize operational performance and enhance research outcomes.

About ProofPilot

ProofPilot is revolutionizing clinical trials with its Clinical Experience Platform, emphasizing a user-friendly approach to streamline site operations and lessen patient burden. Their platform facilitates a smooth, cohesive experience from recruitment to study closure, ultimately resulting in quicker enrollment periods, higher compliance rates, and improved quality across trials. To learn more, visit ProofPilot’s website.

About Lokavant

Lokavant is pioneering AI solutions for study forecasting, reshaping how clinical trials are executed by promoting clarity in an inherently uncertain landscape. Its flagship product, Spectrum, enables teams to independently project enrollment timelines and evaluate operational risks before and during study execution. With advanced AI technologies, Lokavant allows for real-time forecasts achieving over 80% confidence within minutes. The company has demonstrated its ability to significantly reduce non-conformance events and enhance overall study efficiency. More information can be found at Lokavant’s website.